


PHARMACEUTICAL 2022

Nurix Therapeutics Inc. Rank 173 of 475







PHARMACEUTICAL 2022

Nurix Therapeutics Inc. Rank 173 of 475



The relative strengths and weaknesses of Nurix Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nurix Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Nurix Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is -33%, being 243% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	311,118
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	66,258
Liabilities, Non-Current	68,211
Other Assets	154,313
Other Compr. Net Income	-695
Other Expenses	131
Other Liabilities	0
Other Net Income	0
Property and Equipment	11,340
Research and Development	116,434
Revenues	30,573
Selling, General and Administrative Expense	31,202

Output Variable	Value in 1000 USD
Assets	476,771
Liabilities	134,469
Expenses	147,767
Stockholders Equity	342,302
Net Income	-117,194
Comprehensive Net Income	-117,542
Economic Capital Ratio	-33%